We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Obesity, Metabolic Syndrome, and Prediabetes
Center of Excellence
Interested in receiving weekly updates about the Obesity, Metabolic Syndrome, and Prediabetes Center of Excellence?
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Vishal Chopra
Mar 10, 2023
Sglt 2 inhibitors will be appropriate choice for this patient as will take care of weight as well as progression of Nephropathy
Annamaria Noszek
Mar 10, 2023
a,
Otton Souza
Mar 11, 2023
GLP 1 is more apropriated.
Mehwish Saeed
Sep 23, 2023
SGLT 2 inhibitor is appropriate,given the obesity and albuminuria... and preferable over GLP1 agonists due to history of pancreatic in this patient
Mehwish Saeed
Dec 27, 2023
GLP 1a, since it will cause more significant weight loss as compared to SGLT2i... renal benefit is with both. As for pancreatis... likely risk lower than benefit since post cholecystectomy status.
Visala Nanduri
Jan 27, 2024
SGLT2 inhibitors
Apr 26, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Jacqueline
A.
Seiglie
MD, MSc
Vishal Chopra
Mar 10, 2023
Annamaria Noszek
Mar 10, 2023
Otton Souza
Mar 11, 2023
Mehwish Saeed
Sep 23, 2023
Mehwish Saeed
Dec 27, 2023
Visala Nanduri
Jan 27, 2024
Apr 26, 2024
Pending Moderator approval.